- Home
- KAPA vs BTAI Comparison
KAPA vs BTAI Comparison
Compare KAPA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAPA
- BTAI
- Stock Information
- Founded
- KAPA 2013
- BTAI 2017
- Country
- KAPA United States
- BTAI United States
- Employees
- KAPA N/A
- BTAI N/A
- Industry
- KAPA
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- KAPA
- BTAI Health Care
- Exchange
- KAPA NYSE
- BTAI Nasdaq
- Market Cap
- KAPA 19.9M
- BTAI 18.1M
- IPO Year
- KAPA 2024
- BTAI 2018
- Fundamental
- Price
- KAPA $1.63
- BTAI $0.36
- Analyst Decision
- KAPA Strong Buy
- BTAI Buy
- Analyst Count
- KAPA 1
- BTAI 4
- Target Price
- KAPA $9.00
- BTAI $2.81
- AVG Volume (30 Days)
- KAPA 6.1M
- BTAI 1.3M
- Earning Date
- KAPA 02-23-2025
- BTAI 03-11-2025
- Dividend Yield
- KAPA N/A
- BTAI N/A
- EPS Growth
- KAPA N/A
- BTAI N/A
- EPS
- KAPA N/A
- BTAI N/A
- Revenue
- KAPA N/A
- BTAI $2,276,000.00
- Revenue This Year
- KAPA N/A
- BTAI $131.45
- Revenue Next Year
- KAPA N/A
- BTAI $45.65
- P/E Ratio
- KAPA N/A
- BTAI N/A
- Revenue Growth
- KAPA N/A
- BTAI 83.25
- 52 Week Low
- KAPA $0.85
- BTAI $0.30
- 52 Week High
- KAPA $4.00
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- KAPA N/A
- BTAI 45.04
- Support Level
- KAPA N/A
- BTAI $0.33
- Resistance Level
- KAPA N/A
- BTAI $0.39
- Average True Range (ATR)
- KAPA 0.00
- BTAI 0.06
- MACD
- KAPA 0.00
- BTAI -0.00
- Stochastic Oscillator
- KAPA 0.00
- BTAI 16.80
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.